In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 213-224

  Barbuch, Robert J ^a   Campanale, Kristina ^a   Hadden, Chad E ^a   Zmijewski, Milton ^a   Yi, Ping ^a   O'Bannon, Douglas D ^a   Burkey, Jennifer L ^a   Kulanthaivel, Palaniappan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CYTOCHROME P450 2D6; DRUG METABOLITE; RECOMBINANT ENZYME; RUBOXISTAURIN; CARBON; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT; CANNULATION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MORTIERELLA; MORTIERELLA ZONATA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; ANIMAL; BILE; BIOTRANSFORMATION; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; FECES; FISCHER 344 RAT; METABOLISM; MOUSE STRAIN; URINE;

ANIMALIA; CANIS FAMILIARIS; MORTIERELLA;

ANIMALS; BILE; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP2D6; DOGS; ENZYME INHIBITORS; FECES; FEMALE; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MALEIMIDES; MASS SPECTROMETRY; MICE; MICE, INBRED STRAINS; MORTIERELLA; PROTEIN KINASE C; RATS; RATS, INBRED F344;

EID: 31344446194     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007401     Document Type: Article

References (17)

1. Aiello LP, Bursell S, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473-1480.
2. Aiello LP, Bursell SE, Devries T, Alatorre C, King GL, and Ways DK (1999) Amelioration of abnormal retinal hemodynamics by a protein kinase C β selective inhibitor (LY333531) in patients with diabetes: results of a phase 1 safety & pharmacodynamic clinical trial. Invest Ophthalmol Vis Sci 40:S192.
3. Bradshaw D, Hill CH, Nixon JS, and Wilkinson SE (1993) Therapeutic potential of protein kinase C inhibitors. Agents Actions 38:135-147.
4. Burkey JL, Campanale KM, O'Bannon DD, Cramer JW, and Farid NA (2002) Disposition of LY333531, a selective protein kinase C b inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 32:1045-1052.
5. Curtis TM and Scholfield CN (2004) The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 20:28-43.
6. Danis RP, Bingamann DP, Jirousek M, and Yang Y (1998) Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci 39:171-179.
7. Farago A and Nishizuka Y (1990) Protein kinase C in transmembrane signaling. FEBS Lett 268:350-354.
8. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S, Kern TS, Ballas LM, Heath WF, et al. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science (Wash DC) 272:728-731.
9. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, et al. (1996) (S)-13- [(Dimethylamino)methyl]-10,11,14, 15-tetrahydro-4,9:16,21-dimetheno-1H,13H- dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J Med Chem 39:2664-2671.
10. Mellor H and Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281-292.
11. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, et al. (1999) A protein kinase C-[beta]-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48:2090-2095.
12. Newton AC (2003) Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 370:361-371.
13. Nishizuka Y (1986) Studies and perspectives of protein kinase C. Science (Wash DC) 233:305-312.
14. Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cell regulation. Nature (Lond) 334:661-665.
15. 14C] MsOH, a PKCβ inhibitor and its use in QWBA studies in rats, in Synthesis and Applications of Isotopically Labeled Compounds (Dean DC, Filer CN, and McCarthy KE eds) pp 271-274, John Wiley and Sons, New York.
16. Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, Aiello LP, and King GL (2002) Characterization of protein kinase C b isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation and retinal neovascularization. Proc Natl Acad Sci USA 99:721-726.
17. Yokota T, Ma RC, Park J, Isshiki K, Sotiropoulos KB, Rauniyar RK, Bornfeldt KE, and King GL (2003) Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 52:838-845.